Kosamin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kosamin

What is Kosamin? (Tranexamic Acid)

Property Description
Active ingredient Tranexamic Acid
Form Tablet (Oral), Solution for Injection (Intravenous)
Pharmacological class Antifibrinolytic Agent
Common purpose Control and prevent excessive blood loss
Origin Synthetic derivative of the amino acid lysine

Kosamin is a synthetic prescription medication whose defining characteristic is its single active ingredient, Tranexamic Acid. This medicine is classified as a potent Antifibrinolytic Agent. Tranexamic Acid is chemically a synthetic derivative of the essential amino acid lysine, confirming its specialized laboratory origin. This classification defines the medication's specific role in preventing the premature dissolution of blood clots.

The essential purpose of Kosamin is to maintain and support the structural stability of existing blood clots to control and prevent excessive bleeding. It achieves this by focusing on the process of fibrinolysis, which is the body's natural method for dissolving the fibrin mesh that forms a clot. Tranexamic Acid reduces bleeding by inhibiting the breakdown of blood clots. This means the medication helps the body sustain a stable clot for longer, a function that is therapeutically vital in situations of abnormal or uncontrolled hemorrhage.

Kosamin is manufactured as a single active ingredient product in two distinct preparations: the Tablet for oral administration and the Solution for Injection for intravenous use. The availability of both forms ensures the ability to match the route of administration to the clinical need—either controlled systemic delivery for ongoing management or rapid entry into the bloodstream for acute stabilization.

What side effects are possible with Kosamin?

Possible side effects and safety information

The official safety profile for Kosamin (Tranexamic Acid) outlines adverse reactions grouped by frequency and affected body system, strictly according to government regulatory documents. The information is structured to communicate both the frequently observed effects and the rare, serious risks.

Adverse Reactions and Safety Classification

Side effects documented in regulatory labeling are often categorized by the system-organ class (SOC) affected:

  • Gastrointestinal Disorders: Reactions such as nausea, vomiting, and diarrhea are classified among the most commonly reported adverse events.
  • Nervous System Disorders: Reactions documented in this category include giddiness or dizziness.
  • Skin and Immune System Disorders: Allergic dermatitis is a documented adverse reaction, and hypersensitivity reactions, including severe anaphylaxis, are classified in the regulatory text.

Serious Safety Considerations

The most serious adverse reactions listed in the official labeling relate to clotting risk and neurological function. These include the occurrence of thromboembolic events (arterial and venous thrombosis), such as pulmonary embolism or retinal artery/vein occlusion. Seizures (convulsions) are also documented as a serious risk, often associated with high doses or improper administration of the injectable form.

Safety Restrictions and Special Populations

Official prescribing information includes specific limitations on use. Neuraxial administration (e.g., intrathecal or epidural injection) is contraindicated due to the potential for fatal adverse reactions. Furthermore, patients with renal impairment require a mandatory dose reduction as specified in the label to prevent accumulation of the medicine. The use of the medication is also contraindicated in individuals with a history of thromboembolic disease or specific color vision defects documented in the labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Kosamin (Tranexamic Acid) overdose focuses on acute systemic manifestations and the potential for severe vascular complications. Documented presentations primarily involve the central nervous system, gastrointestinal tract, and the vascular system. Symptoms officially cited in regulatory documents include neurological effects such as convulsions, visual disturbances, and changes in mental status, alongside gastrointestinal distress, hypotension (low blood pressure), and the appearance of a rash.

The most severe outcomes cited in the official labeling relate to the risk of thromboembolic events, specifically arterial or venous thrombosis. These potentially life-threatening complications, such as pulmonary embolism or cerebral thrombosis, mandate urgent medical attention.

Emergency medical help is explicitly required by official regulatory guidance for individuals who exhibit any severe systemic reaction or neurological signs. Treatment, as described in regulatory documents, is primarily supportive. Management procedures may include the consideration of gastric lavage or administration of activated charcoal to limit absorption. A specific regulatory note highlights that patients with impaired renal function are at an increased risk of accumulation and toxicity due to reduced clearance, necessitating heightened awareness in this population.

Therapeutic Uses of Kosamin

What Kosamin Treats: Main Uses and Benefits

Kosamin may be part of symptomatic management in clinical situations characterized by significant or excessive bleeding, offering symptomatic relief in situations involving blood loss. Its application spans both conditions involving episodic or fluctuating manifestations and clinical settings that involve acute or unstable symptom patterns. The medication serves as a supportive therapy in managing excessive blood loss.


Therapeutic Applications and Benefits

Kosamin is commonly used to help with symptoms related to systemic imbalance, specifically cyclic heavy menstrual bleeding (menorrhagia) and other forms of abnormal uterine bleeding, as well as severe hemorrhage following major trauma, childbirth (postpartum hemorrhage), and complex surgery. It is also relevant for managing localized and recurrent bleeding symptoms, such as severe nosebleeds (epistaxis) or bleeding associated with certain procedural risks.

“This symptomatic support is often used when short-term symptomatic assistance is needed to address increased discomfort or tension related to blood loss.”

This use contributes to improved comfort during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability when bleeding interferes with routine activities. The medication provides support that helps ease the overall symptom burden in critical episodes.

Quick Fact: Relief for Heavy Menstrual Symptoms Kosamin is commonly used to help with reducing the volume of blood lost during the menstrual cycle, a key benefit that helps improve day-to-day comfort for women with menorrhagia.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Kosamin

Kosamin (Tranexamic Acid) eligibility is defined by official regulatory documentation, primarily based on vascular status, organ function, and age.

Populations for Whom Use is Contraindicated:

Individuals who must not use Kosamin include those with active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism) or an intrinsic risk of clotting. The oral form is contraindicated for females using combined hormonal contraceptives. Use is also prohibited in patients with severe renal impairment or a known hypersensitivity to the medicine. The intravenous form is specifically contraindicated in cases of subarachnoid hemorrhage and for patients with a history of convulsions.

Age and Reproductive Status:

  • Pediatric: The oral form is not intended for females under 12 years of age for heavy menstrual bleeding. The intravenous form may be used in children from one year, though data are limited.
  • Pregnancy and Lactation: Use during pregnancy is restricted and recommended only if the expected benefit outweighs potential risk. Breastfeeding is not recommended because the drug is excreted in human milk.

Conditional Use:

Patients with mild to moderate renal impairment require mandatory dosage adjustments, as stated in regulatory guidelines. Patients with hematuria from the upper urinary tract have restricted use due to the risk of clot obstruction.

What should I know about interactions with other medicines?

The interaction profile for Kosamin (Tranexamic Acid) is strictly defined by regulatory documents, focusing on documented pharmacodynamic risks and clearance considerations.

Formal Restrictions and High-Risk Combinations

Co-administration with Combined Hormonal Contraceptives (containing estrogen and progestin) is formally contraindicated by regulatory agencies. This classification is due to a documented increase in the risk of serious thromboembolic adverse reactions when these agents are used together.

Use of Kosamin is also not recommended with certain pro-thrombotic medical products, including Factor IX Complex Concentrates and Anti-Inhibitor Coagulant Concentrates, as official documents state this may further increase the risk of blood clot formation. Similarly, co-administration with Oral Tretinoin is discouraged in patients with acute promyelocytic leukemia because of a possible procoagulant effect.

Pharmacodynamic Antagonism and Clearance

The antifibrinolytic action of Kosamin may be antagonized by co-administered Tissue Plasminogen Activators (fibrinolytic preparations), which can lead to a documented decrease in the efficacy of both agents.

Furthermore, since Kosamin is substantially cleared by the kidneys, official labels specify that impaired renal function is associated with reduced clearance, creating a risk of increased plasma concentration. The oral tablet formulation may be taken with or without food.

Mechanism of Action

Molecular Mimicry and Target Inhibition

Kosamin (Tranexamic Acid) acts as a competitive inhibitor within the fibrinolytic system. The drug's structure functions as a synthetic lysine analogue, granting it affinity for the Lysine Binding Sites (LBS) on the inactive protein plasminogen. This reversible molecular interaction is the initiating step that governs the drug's downstream physiological consequence.

Fibrinolytic Pathway Modulation

By occupying the LBS, the drug physically blocks plasminogen from anchoring itself to the fibrin mesh of an existing clot, which is the crucial binding step required for clot breakdown. This targeted intervention prevents the localized, enzyme-mediated destruction of the clot structure by suppressing the formation of the active enzyme plasmin. The physiological result is the sustained integrity of the existing fibrin clot structure, protecting it from enzymatic degradation.

Mechanistic Dependencies

This antifibrinolytic action is strictly limited to stabilizing a clot that is already formed. The mechanism does not possess the capacity to initiate or accelerate the primary coagulation cascade, defining its specialized, dependency-constrained role within hemostasis.

Dosage and Administration Information

The administration of Kosamin (Tranexamic Acid) is standardized and depends on the intended clinical use, utilizing either the Oral Tablet or the Solution for Injection. The usage patterns define both the route and the time limits for therapy. The medicine may be administered orally or intravenously; however, the injection is restricted to the IV route and is not administered intramuscularly or into the spine.


Official Dosing and Administration

Dosing and Frequency: For the oral regimen used in managing heavy menstrual bleeding, the dose is 1300 mg (delivered as two tablets) taken three times a day (TID). In contrast, the intravenous dose for general control of fibrinolysis is typically 0.5 g to 1 g per dose, administered two to three times daily. This regimen involves a 10 mg/kg dose for procedures such as dental extractions.

Use Duration and Timing: Kosamin is used for short-term periods. Oral treatment is limited to a maximum of five consecutive days during the menstrual cycle and is not for continuous daily consumption. Tablets can be taken with or without food but must be swallowed whole to ensure proper systemic delivery.

Special Administration Rules: Dosing modification applies to patients with impaired renal function, with reductions based on serum creatinine levels. When administered intravenously, the solution is infused very slowly, at a rate generally not exceeding 1 mL/minute.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kosamin (Tranexamic Acid)

Evidence for Use in Heavy Menstrual Bleeding (Menorrhagia)

Research examining Kosamin's use in conditions such as heavy menstrual bleeding primarily relies on short- to intermediate-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored short-term symptom changes, and outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies, including patient-reported outcomes describing perceived discomfort which were tracked over defined time intervals, typically three to six menstrual cycles.

What remains uncertain is the potential for long-term consistency of these patterns after administration is stopped, as follow-up durations were limited. Comparative evidence is lacking against long-term therapies, such as specific hormonal options, and its relative research profile is not fully established.

Evidence for Use in Managing Significant Acute Bleeding (Trauma and PPH)

The evidence base for using Kosamin in acute, disruptive episodes of bleeding, particularly following major trauma or childbirth (postpartum hemorrhage, PPH), was evaluated in large-scale, international RCTs. These trials examined outcomes reflecting episodic or acute changes, with the central focus being on patient survival and the need for blood product transfusions. Research suggests that time of administration was a factor, with administration later than three hours after the bleeding event observed to be associated with a different pattern of outcomes in some trauma studies. Research is less extensive regarding its use purely for prevention (prophylaxis) compared to the evidence exploring its use for treatment.

Evidence for Use in Controlling Surgical Blood Loss

Kosamin was studied for its use in adult patients undergoing major elective surgery. Numerous RCTs and meta-analyses monitored outcomes related to total measured blood loss volume and the requirement for blood product transfusions both during and immediately following the procedure. Studies reported measurements of blood loss volume that were tracked between intervention and control groups.

What is Still Uncertain About Kosamin

Long-term effects are not fully established because follow-up durations were limited in nearly all major indication studies. Also, the subgroup findings are uncertain regarding the evaluation of this medicine in patients with rare underlying bleeding disorders or specific severe comorbidities. Evidence quality varies across studies due to the wide range of dosing protocols and outcome definitions used.

Frequently Asked Questions (FAQ)

Common questions about Kosamin (FAQ)


Q: Does Kosamin interact with common pain relievers like Tylenol (acetaminophen)?

Official regulatory documents do not typically list specific information regarding interactions between Kosamin (Tranexamic Acid) and common over-the-counter pain relievers like acetaminophen. The formal drug label focuses primarily on documented high-risk combinations, such as hormonal contraceptives or certain agents that promote clotting.


Q: Is it okay to use Kosamin if I am already taking blood thinners?

Official product information advises caution regarding the use of Kosamin with other medicines that affect the clotting process. Using it with certain pro-thrombotic agents (those that increase the risk of clotting) is not recommended. Concerns about combining medicines are best clarified using the official drug label or by consulting regulatory documents.


Q: Are there any known interactions with common over-the-counter cold and flu medicines?

Regulatory safety documents prioritize detailing specific, documented drug-to-drug interactions that carry a significant risk. General warnings or information regarding common over-the-counter cold and flu medicines are not routinely detailed in the core drug label. The lack of detail in the core label means that information is not routinely provided by regulatory bodies.


Q: What are the official sources to check for updates or new safety information about Kosamin?

Authoritative sources for the most current and official safety updates about Kosamin (Tranexamic Acid) include government drug agencies. These generally involve the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH) through platforms like MedlinePlus or DailyMed.


Q: Is there a possibility of becoming dependent on Kosamin?

Regulatory reviews of Kosamin (Tranexamic Acid) generally do not classify it as a drug with potential for abuse or dependency. It is not listed as a controlled substance in major governmental drug schedules.


Q: How long does Kosamin stays in the body after the last use?

Pharmacokinetic data from official documents indicate that the apparent elimination half-life of Kosamin is approximately two hours. The drug is largely cleared by the kidneys, with most elimination occurring within the first eight hours after administration.


Q: Can Kosamin cause sleep disturbances or changes in energy levels?

The official safety profile lists some nervous system side effects, such as dizziness or giddiness. While drowsiness is mentioned as a possible effect in some safety documents, the core regulatory safety profile does not generally detail changes to sleep patterns or energy levels.


Q: Is the effect of Kosamin supposed to be immediate or gradual?

For acute, severe bleeding situations, research suggests that outcomes reflect when administration occurred relative to the bleeding event. For the oral form used in conditions like heavy menstrual bleeding, the treatment is short-term and cyclical, suggesting a targeted effect during the period of use.


Q: Does Kosamin have different conditions of use in other countries?

Yes, the approved conditions of use for Kosamin (Tranexamic Acid) can vary between regulatory authorities globally. Differences may exist in approved maximum daily doses, specific medical indications, or administration guidelines, as defined by their respective regulatory agencies (e.g., EMA vs. FDA).


Q: Can using Kosamin impact a person's mood or mental state?

Official safety data lists effects on the nervous system, such as dizziness and giddiness, and serious neurological risks like seizures. While mood changes are not commonly reported, these documented effects are categorized under the nervous system.


Q: How does Kosamin relate to natural compounds found in the body?

Kosamin is a synthetic derivative of the essential amino acid lysine. It functions by mimicking lysine's structure, which allows it to bind to the lysine-binding sites on the protein plasminogen. This specific action helps to stabilize existing blood clots.


Q: Can Kosamin cause changes to my skin or hair?

Official safety documents list allergic dermatitis and other allergic skin reactions as documented side effects. Other non-specific changes to skin or hair, such as hair loss, are not routinely detailed in the core regulatory product information.


Q: Does Kosamin need to be used at a specific time of day for best results?

For approved conditions, official patient instructions generally state that the drug is taken three times a day at around the same times each day you are scheduled to receive a dose. Official instructions highlight the importance of consistency in the administration schedule.


Q: What is the expected long-term safety profile of Kosamin?

The official research evidence overview notes that the long-term safety of Kosamin is not fully established. This is because the follow-up durations in nearly all major clinical studies for its approved indications were limited.


Q: Does taking Kosamin affect my ability to drive or focus?

Because Kosamin can cause nervous system effects like dizziness or giddiness, patient information leaflets often contain warnings about driving or operating complex machinery. Due to these potential side effects, caution is advised.


Q: Are there official recommendations for what to do if a side effect occurs?

Official patient information requires seeking immediate medical attention if a serious side effect, such as unexpected pain, swelling, or changes in eyesight, occurs. This is based on the instructions provided in regulatory documents.

How should Kosamin be stored and disposed of?

Kosamin must be stored and disposed of according to strict requirements defined in government-approved labeling.

Official Storage Requirements

Storage Classification Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C); excursions are permitted to 15 C to 30 C.
Container Protection Keep the medicine in its original, tightly closed container and protect from light.
Prohibited Conditions Do not freeze and avoid exposure to excessive heat.
Child Safety Store the medication out of the sight and reach of children.

Handling and Disposal

For the injection form, the diluted solution has an in-use stability limit and should be administered promptly; any unused portion must be discarded. To prevent medication errors, regulatory guidance suggests not storing the injection near local anesthetics. Disposal of unused or expired medicine must follow labeled instructions or utilize a drug take-back program. If no program is available, the drug must be mixed with an undesirable substance (e.g., coffee grounds) and sealed in a container before disposal in household trash. It should not be flushed down a toilet unless explicitly instructed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kosamin found in:

A-Z Index: